Corline Biomedical AB (CLBIO) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.029x

Based on the latest financial reports, Corline Biomedical AB (CLBIO) has a cash flow conversion efficiency ratio of -0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.20 Million ≈ $-237.19K USD) by net assets (Skr77.23 Million ≈ $8.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Corline Biomedical AB - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Corline Biomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CLBIO liabilities breakdown for a breakdown of total debt and financial obligations.

Corline Biomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Corline Biomedical AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
3U Holding AG XETRA:UUU	-0.237x
Entropy Neurodynamics Limited AU:ENP	-0.459x
Opnet Technologies Co Ltd TWO:8034	0.030x
B&B Triplewall Containers Limited NSE:BBTCL	0.050x
Vate Technology Co Ltd TWO:5344	-0.022x
Orient Paper & Industries Limited NSE:ORIENTPPR	-0.007x
Gigas Hosting S.A MC:GIGA	0.084x
Johnson Matthey PLC LSE:JMAT	0.176x

Annual Cash Flow Conversion Efficiency for Corline Biomedical AB (2013–2024)

The table below shows the annual cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see CLBIO stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr86.91 Million ≈ $9.35 Million	Skr-8.64 Million ≈ $-929.69K	-0.099x	-1146.88%
2023-12-31	Skr93.32 Million ≈ $10.04 Million	Skr886.00K ≈ $95.35K	0.009x	+113.92%
2022-12-31	Skr94.59 Million ≈ $10.18 Million	Skr-6.45 Million ≈ $-694.34K	-0.068x	-30.12%
2021-12-31	Skr92.23 Million ≈ $9.93 Million	Skr-4.83 Million ≈ $-520.32K	-0.052x	+46.16%
2020-12-31	Skr52.03 Million ≈ $5.60 Million	Skr-5.07 Million ≈ $-545.18K	-0.097x	+58.27%
2019-12-31	Skr59.32 Million ≈ $6.38 Million	Skr-13.84 Million ≈ $-1.49 Million	-0.233x	-212.44%
2018-12-31	Skr54.96 Million ≈ $5.91 Million	Skr-4.10 Million ≈ $-441.66K	-0.075x	+31.11%
2017-12-31	Skr45.93 Million ≈ $4.94 Million	Skr-4.98 Million ≈ $-535.71K	-0.108x	+41.76%
2016-12-31	Skr38.75 Million ≈ $4.17 Million	Skr-7.21 Million ≈ $-776.02K	-0.186x	+6.53%
2015-12-31	Skr21.25 Million ≈ $2.29 Million	Skr-4.23 Million ≈ $-455.34K	-0.199x	+52.91%
2014-12-31	Skr5.48 Million ≈ $590.25K	Skr-2.32 Million ≈ $-249.55K	-0.423x	-22.53%
2013-12-31	Skr8.00 Million ≈ $860.60K	Skr-2.76 Million ≈ $-296.95K	-0.345x	--

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$42.30 Million

Skr393.08 Million SEK

Market Cap Rank

#22495 Global

#416 in Sweden

Share Price

Skr16.05

Change (1 day)

-0.62%

52-Week Range

Skr9.66 - Skr21.20

All Time High

Skr28.20